<a href="https://www.fiercebiotech.com/biotech/vincentage-sees-124-weight-loss-oral-glp-1-will-chase-lilly-chinese-regulators" hreflang="en">Vincentage sees 12.4% weight loss for oral GLP-1, will chase Lilly to Chinese regulators</a>
fiercebiotech.com·May 18, 2026
Vincentage Pharma's oral GLP-1 agonist has demonstrated an average weight loss of 12.4% over a year, positioning the company to seek regulatory approval in China for Eli Lilly's orforglipron.
The key learning here is that Vincentage Pharma's oral GLP-1 agonist, demonstrating significant weight loss results, positions the company strategically to challenge Eli Lilly's orforglipron in the Chinese market. This development signals a competitive landscape in obesity treatment within China, potentially impacting investment strategies and collaboration opportunities for stakeholders in biotech and pharmaceutical sectors focusing on metabolic disorders.